放射性核素标记生长抑素类似物在淋巴瘤中的应用

赵德善

赵德善

文章导航 > 国际放射医学核医学杂志 > 2004, 28 > 5: (206-209)

引用本文:

Citation:

放射性核素标记生长抑素类似物在淋巴瘤中的应用

赵德善

030001 太原, 山西医科大学第一医院核医学科
中图分类号: R817.4;R817.5

The role of radionuclide-labeled somatostatin analogues in lymphoma

ZHAO De-shan

Department of Nuclear Medicine, No.1 Hospital of Shanxi Medical University, Taiyuan 030001, China
CLC number: R817.4;R817.5

摘要: 生长抑素类似物如奥曲肽、depreotide等与生长抑素受体作用时间长、亲和力高,并可被放射性核素标记,用于肿瘤的生长抑素受体显像和治疗。淋巴瘤细胞表达该受体,因此可利用生长抑素受体对其进行显像和治疗。大量临床和实验研究均表明,放射性核素标记生长抑素类似物的生长抑素受体显像可对淋巴瘤进行诊断、分期、治疗和预后的评价,也可作为常规影像学显像、⁶⁷Ga和PET显像诊断、评价淋巴瘤的一种有力补充。而在淋巴瘤治疗中的应用应当慎重,如何能获得最佳治疗效果而又将其副作用减小到最低程度是今后研究的主要课题之一。
- 生长抑素类似物 /
- 生长抑素受体 /
- 奥曲肽 /
- 淋巴瘤 /
- 生长抑素受体显像 /
- 治疗
Abstract: Somatostatin analogues, such as octreotide, depreotide and so on, having long-time and high affinity with somatostatin receptors(SSTR) and labeled by radionuclides, can be used in SSTR scintigraphy and treatment of tumors expressing SSTR. Moreover, Lymphoma express SSTR(SSTR2 and SSTR3). A series of clinical and experimental results showed SSTR scintigraphy is an interesting way to evaluate the diagnosis, staging, treatment and prognosis of lymphoma, and a supplemental tool of diagnosing and judging lymphoma with conventional X-rays imaging, ⁶⁷Ga and PET. Whereas, the application of radionuclide-labeled somatostatin analogues in treatment of lymphoma should be cautiously performed. Recently it is a concerned question how the patients suffering from lymphoma can have the most profits and the least side-effects from the treatment of radionuclide-labeled somatostatin analogues.
- somatostatin analogues /
- somatostatin receptors /
- octreotide /
- lymphoma /
- somatostatin receptors scintigraphy /
- treatment
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Cascini GL,Cuccurullo V,Rambaldi PF,et al.Immunological imaging using tagged octreotide[J].Minerva Endocrinol, 2001,26(3):129-133.
[2]	Patel YC.Somatostatin and its receptors family[J].Frontier Neu-roendocrinol,1999,20(3):157-198.
[3]	Schonbrunn A.Somatostatin receptors present knowledge and future directions[J].Annal Oncol,1999,10(Suppl 2):s17-s21.
[4]	Feniuk W,Jarvie E,Luo J,et al.Selective somatostatin sst2 receptor blockade with the novel cyclic octapeptide,CYN-154806[J].Neuropharmacology,2000,39(8):1443-1450.
[5]	Reubi JC,Waser B,van Hagen M,et al.In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas[J].Int J Cancer,1992,50(6):895-900.
[6]	Dalm VA,Hofland LJ,Mooy CM,et al.Somatostatin receptors inmalignant lymphomas:targets for radiotherapy[J].J Nucl Med,2004,45(1):8-16.
[7]	Virgolini I,Traub T,Novotny C,et al.New trends in peptide receptor radioligands[J].Q J Nucl Med,2001,45(2):153-159.
[8]	Decristoforo C,Mather SJ,Cholewinski W,et al.^99mTc-EDDA/HYNIC-TOC:a new ^99mTc-labelled radiopharmaceutical for somatostatin receptor-positive tumors:first clinical results and intra-patient comparison with ¹¹¹In-labelled octreotide derivatives[J].Eur J Nucl Med,2000,27(9):1318-1325.
[9]	Gabriel M,Decristoforo C,Donnemiller E,et al.An intrapatientcomparison of ^99mTc-EDDA/HYNIC-TOC with ¹¹¹In-DTPA-oc-treotide for diagnosis of somatostatin receptor-expressing tumors[J].J Nucl Med,2003,44(5):708-716.
[10]	Decristoforo C,Melendez-Alafort L,Sosabowski JK,et al.^99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors:preclinical evaluation and comparison with In-oc-treotide[J].J Nucl Med,2000,41(6):1114-1119.
[11]	Virgolini I,Leimer M,Handmaker H,et al.Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer,^99mTc-P829[J].Cancer Res,1998,58(9):1850-1859.
[12]	Machac J,Krynyckyi B,Kim C.Peptide and antibody imaging in lung cancer[J].Semin Nucl Med,2002,32(4):276-292.
[13]	Lipp RW,Schnedl WJ,Aglas F,et al.Visualization of non-Hodgkin's lymphoma by high dosed somatostatin receptor specific scintigraphy and extended single photon emission tomography[J].Acta Med Austriaca,1999,26(3):105-108.
[14]	Li S,Kurtaran A,Li M,et al.¹¹¹In-DOTA-dPhe1-Tyr3-octreotide,¹¹¹In-DOTA-lanreotide and ⁶⁷Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the M ALT type:a comparative study[J].Eur J Nucl Med Mol Imag,2003,30(8):1087-1095.
[15]	Raderer M,Traub T,Formanek M,et al.Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type[J].Br J Cancer,2001,85(10):1462-1466.
[16]	van den Anker-Lugtenburg PJ,Lowenberg B,Lamberts SW,et al.The relevance of somatostatin receptor expression in malignant lym-phomas[J].Metabolism,1996,45(8 Suppl 1):96-97.
[17]	Lipp RW,Silly H,Ranner G,et al.Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy[J].J Nucl Med,1995,36(1):13-18.
[18]	Reubi JC,Schaer JC,Wenger S,et al.SST3-selective potent pep-tidic somatostatin receptor antagonists[J].Proc Natl Acad Sci USA,2000,97(25):13973-13978.

[1]	段炼 , 李险峰 . 甲状腺相关眼病与生长抑素受体显像. 国际放射医学核医学杂志, 2005, 29(3): 108-111.
[2]	向艳 , 夏劲松 . 生长抑素类似物及其标记核素. 国际放射医学核医学杂志, 2002, 26(1): 21-24.
[3]	刘淼 , 刘兴党 . 生长抑素受体显像剂⁹⁹Tc^m-奥曲肽的SPECT研究. 国际放射医学核医学杂志, 2012, 36(3): 138-141. doi: 10.3760/cma.j.issn.1673-4114.2012.03.003
[4]	武鸿文 , 管昌田 . ^99mTc标记生长抑素类似物作为受体显像剂及其特性研究. 国际放射医学核医学杂志, 1998, 22(4): 158-161.
[5]	马寄晓 , 叶大铸 . 奥曲肽及其类似物用于肿瘤治疗的进展. 国际放射医学核医学杂志, 2005, 29(2): 79-84.
[6]	王佳琼 , 王自正 , 姚薇萱 , 王峰 . 乳腺肿瘤生长抑素受体表达与生长抑素受体显像. 国际放射医学核医学杂志, 2006, 30(1): 17-21.
[7]	叶大铸 , 马寄晓 . 奥曲肽及其类似物用于肿瘤诊断的进展. 国际放射医学核医学杂志, 2003, 27(3): 97-100.
[8]	潘永祥 , 王风 , 丁立新 , 杨志 . ⁶⁸Ga-奥曲肽PET/CT显像患者对周围人群产生的有效剂量的估算. 国际放射医学核医学杂志, 2022, 46(12): 713-717. doi: 10.3760/cma.j.cn121381-202202007-00245
[9]	高玉婷 , 王自正 . 生长抑素类似物介导靶向显像及治疗的研究现状和进展. 国际放射医学核医学杂志, 2009, 33(6): 330-334. doi: 10.3760/cma.j.issn.1673-4114.2009.06.003
[10]	钱忠豪 , 赵惠杨 . 类癌瘤综合征左室心肌摄取标记生长抑素类似物. 国际放射医学核医学杂志, 1996, 20(6): 260-261.

点击查看大图

计量

文章访问数: 1362
HTML全文浏览量: 124
PDF下载量: 5

放射性核素标记生长抑素类似物在淋巴瘤中的应用

赵德善

030001 太原, 山西医科大学第一医院核医学科

收稿日期: 2004-04-10

关键词:

摘要: 生长抑素类似物如奥曲肽、depreotide等与生长抑素受体作用时间长、亲和力高,并可被放射性核素标记,用于肿瘤的生长抑素受体显像和治疗。淋巴瘤细胞表达该受体,因此可利用生长抑素受体对其进行显像和治疗。大量临床和实验研究均表明,放射性核素标记生长抑素类似物的生长抑素受体显像可对淋巴瘤进行诊断、分期、治疗和预后的评价,也可作为常规影像学显像、⁶⁷Ga和PET显像诊断、评价淋巴瘤的一种有力补充。而在淋巴瘤治疗中的应用应当慎重,如何能获得最佳治疗效果而又将其副作用减小到最低程度是今后研究的主要课题之一。